

Paper #12

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Complete if Known	
	Application Number	09/648,569
	Filing Date	August 25, 2000
	First Named Inventor	Anders, Hjelholt Pedersen
	Group Art Unit	1633 1647
	Examiner Name	Unassigned J. Schorva Seyon
Attorney Docket Number		31-107600US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
JS	AA	4,588,585		Mark et al.	05-13-1986	
	AB	4,686,191		Itoh et al.	08-11-1987	
	AC	4,769,233		Bell et al.	09-06-1988	
	AD	4,904,584		Shaw	02-27-1990	
	AE	4,914,033		Bell et al.	04-03-1990	
	AF	4,917,888		Katre et al.	04-17-1990	
	AG	4,966,843		McCormick et al.	10-30-1990	
	AH	5,218,092		Sasaki et al.	08-06-1993	
	AI	5,376,567		McCormick et al.	12-27-1994	
	AJ	5,382,657		Karasiwicz et al. Hoffmann-La Roche Inc.	01-17-1995	
	AK	5,545,723		Goelz et al.	08-13-1996	
	AL	5,795,779		McCormick et al.	08-18-1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
JS	AM	WO	95/25170		Biogen, Inc.	09-21-1995		
	AN	WO	98/48018		Fraun-Hofer-Gesellschaft Zur Forderung Der Angewandten	10-29-1998		
	AO	WO	99/03887		Bolder Biotechnology	01-28-1999		
	AP	WO	99/55377		Applied Research	11-04-1999		
	AQ	WO	99/67291		Immunex Corporation	12-29-1999		
	AR	WO	00/23114		Biogen, Inc.	04-27-2000		


Examiner Signature	<i>[Signature]</i>	Date Considered	9/27/02
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Substitute for form 1449A-B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	<b>09/648,569</b>
	Filing Date	<b>August 25, 2000</b>
	First Named Inventor	<b>Anders, Hjelholt Pedersen</b>
	Group Art Unit	<b>1633 - 1647</b>
	Examiner Name	<b>Unassigned J. Schovackyan</b>
	Attorney Docket Number	<b>31-107600US</b>

35	AS	WO	00/23472		Biogen, Inc.	04-27-2000		
	AT	WO	00/26354		Novo Nordisk	05-11-2000		
	AU	EP	083 069		Kyowa Hakko Kogyo Co., Ltd.	09-16-1987		
	AV	EP	041 313		Biogen, Inc.	09-12-1990		
	AW	EP	229 108		Cetus Corporation	12-27-1990		
	AX	EP	260 350		Cetus Corporation	02-12-1992		
	AY	EP	287 075		Arzeneimittelforschung /Drug Research	01-18-1995		
8	AZ	EP	539 300		Philippe Thiriet	02-07-1996		
	BA	EP	593 868		Hoffmann-La Roche Inc.	04-15-1998		


OTHER PRIOR ART - NON PATECNT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	
35 ↓	BB	Fierlbeck et al., "Neutralising interferon $\beta$ antibodies in melanoma patients treated with recombinant and natural interferon $\beta$ " <u>Cancer Immunol Immunother</u> (1994) 39:263-268		
	BC	Karpusas et al., "The Structure of Human Interferon- $\beta$ : Implications for activity" <u>CMLS</u> 54 (1998) 1203-1216		
	BD	Karpusas <i>et al.</i> "The crystal structure of human interferon $\beta$ at 2.2 A resolution" Proc. Nat. Acad. Sci. USA (1997) 94:11813-11818		
	BE	Mayorga et al., "Antibodies to Commercially Available Interferon-Bet Molecules in Multipule Sclerosis Patients Treated with Natural Interferon-Beta" <u>Int. Arch. Allery Immunol</u> 1999; 118:368-371		
	BF	Munschauer et al., "Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multipule Sclerosis" <u>Clinical Therapeutics</u> vol. 19, No. 5, 1997 883-893		
	BG	Redlich et al., "Antibodies that neutralize human $\beta$ interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping" <u>Proc. Natl. Acad. Sci. USA</u> vol. 88, pp. 4040-4044 May 1991		

Examiner Signature		Date Considered	9/27/02
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Substitute for form 1449A-B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	<b>09/648,569</b>
	Filing Date	<b>August 25, 2000</b>
	First Named Inventor	<b>Anders, Hjelholt Pedersen</b>
	Group Art Unit	<b>1633-1647</b>
	Examiner Name	<b>Unassigned J. Sahara Sayon.</b>
	Attorney Docket Number	<b>31-107600US</b>

SS	BH	Rudick et al., "Incidence and significance of neutralizing antibodies to interferon beta-1a in multipule sclerosis" <u>Neurology</u> May 1889, 50: 1266-1272	
	BI	Runkel et al., "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- $\beta$ (IFN- $\beta$ )" <u>Pharmaceutical Research</u> vol. 15, No 4, 1998, 641-649	
	BJ	Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between $\alpha$ and $\beta$ Type I Interferons Explored by Mutational Analysis" 273, No. 14, pp. 8003-8008	
	BK	Senda et al., "Refined Crystal Structure of Recombinant Murine Interferon- $\beta$ at 2.15 A Resolution" <u>J. Mil. Biol.</u> (1995) 253, 187-207	
	BL	Stewart et al, DNA "Chemical Mutagenesis of Human Interferon- $\beta$ : Construction, Expression in E. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations Vol 6 no 2 1987 p119-128	
	BM	Tanigunchi, et al., "The nucleotide sequence of human fibroblast interferon cDNA" <u>Gene</u> 10 (1980) 11-15	
	BN	Yong et al., "Interferon beta in the treatment of multiple sclerosis" <u>Neurology</u> 1998; 51: 682-689	

Examiner Signature		Date Considered	9/27/02
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	09/648,569
	Filing Date	August 25, 2000
	First Named Inventor	A. H. Pedersen
	Group Art Unit	1647
	Examiner Name	J. Seharaseyon
	Attorney Docket Number	0202us810

RECEIVED  
 TECH CENTER  
 02 SEP 20  
 10:2:34

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
JS	1	5,206,344		Katre et al.	04/27/1993	
JS	2	5,738,846		Greenwald et al.	04/14/1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
JS	3	EP	0 370 205	A2	Kyowa Hakko Kogyo Co., Ltd.	05/30/1990		
	4	EP	0 529 300	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		X
	5	EP	0 529 300 (English language translation of document #4)	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		
	6	WO	95/27502	A1	Research Development Foundation	10/19/1995		
	7	WO	98/35026	A1	Novo Nordisk A/S	08/13/1998		
JS	8	WO	99/55377	A2	Applied Research Systems	11/04/1999		

OTHER ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
JS	9	Derwent Abstract 012152872 for WO 98/48018, a German publication cited in previous IDS Form 1449.		
	10	<del>Derwent Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form 1449.</del>		

Examiner Signature		Date Considered	9/27/02
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.